5aCdR	5-aza-2′-deoxycytidine.
5hmC	5-hydroxymethylcytosine.
5hmC	hydroxymethyl cytosine.
5mC	5-methylcytosine.
AE	adverse event.
ALT	alternative lengthening of telomeres pathway.
Alu	arthrobacter luteus DNA repeats.
AML	acute myeloid leukemia.
AOP	adverse outcome pathway.
APC	adenomatous polyposis coli protein.
B[a]P	benzo[a]pyrene.
BCAT1	branched-chain-amino-acid aminotransferase, cytosolic.
BEAS-2B	human bronchial epithelial SV-40 immortalised cell line.
BMD	benchmark-doses.
BMP3	bone morphogenic protein 3.
BPA	bisphenol-A.
CAN	copy number alterations.
CAR	constitutive androstane receptor.
cGAS	cyclic GMP-AMP synthase.
CTA	cell transformation assay.
CTAG	cancer-testis antigens.
CTCF	CCCTC-binding factor.
DNAm	DNA methylation.
DNMT1, 2, 3a, 3b, 3L	DNA methyltransferases.
Ecad	E-cadherin.
EMT	epithelial to mesenchymal transition.
GGD	global genome DNA.
GGDHo	global genome DNA hypomethylation.
GGDm	global genome DNA methylation.
GSH	glutathione.
GSTP1	glutathione S-transferase Pi1.
GTxC	genotoxic carcinogens.
HA	hazard assessment.
HaCaT	human keratinocyte immortalized cell line.
HBE	human bronchial epithelial cell line.
HCA	high-content analysis.
HDAC	histone deacetylase.
HDM	histone demethylase.
hESC	human embryonic stem cells.
HMEC	human mammary epithelial cells.
HMT	histone methyltransferase.
HPTM	histone post-translational modifications.
HTS	high-throughput screening.
HUC1	human urothelial immortalised cell line.
IARC	International Agency for the Research on Cancer.
IATA	integrated approach to the testing and assessment.
IDH	isocitrate dehydrogenase.
IKZF1	DNA-binding protein Ikaros.
KDM	lysine demethylase.
KE	key event.
KER	key event relationship.
KMT	lysine methyltransferase.
L-02	human hepatic cell line.
Line	long interspersed nuclear element.
LncRNA	long non-coding RNA.
LOAELs	lowest-observable-adverse-effect levels.
LTR	long terminal repeat.
MCF7	breast cancer cell line #7 from the Michigan Cancer Foundation.
mESC	mouse embryonic stem cells.
MGMT	methylated DNA-protein-cysteine methyltransferase.
MHC	major histocompatibility complex.
MIE	molecular initiating event.
MS	mass spectrometry.
NAM	novel approach methodologies.
ncRNA	non-coding RNA.
NDRG4	N-myc downregulated gene 4.
NGS	next-generation sequencing.
NGTxC	non-genotoxic carcinogens.
NOAELs	no-observable-adverse- effect levels.
OECD	Organization for Economic Cooperation and Development,
OGG1	8-oxoguanine glycosylase.
ONECUT2	one cut domain family member 2.
OTX1	homeobox protein OTX1.
PBMC	peripheral blood mononuclear cells.
PCB	polychlorinated biphenyls.
PCNA	proliferative cell nuclear antigen.
PHD	prolyl hydroxylase dioxygenase.
PND	postnatal day.
PoD	point of departure.
RA	risk assessment.
RASSF1	ras association domain-containing protein 1.
RCB	two-year rodent cancer bioassay.
RRBS	reduced-representation bisulphite sequencing.
SAHA	suberoylanilide hydroxamic acid.
SAM	s-adenosylmethionine.
09-Sep	septin-9.
SHOX2	short stature homeobox protein 2.
Sine	short interspersed nuclear element.
SUV39H1	suppressor of variegation 3–9 homolog 1; catalyzes H3K9me3.
TCA	tricarboxylic acid cycle.
TCDD	2,3,7,8-tetrachlorodibenzo-p-dioxin.
TDG	thymine-DNA glycosylase.
TET-1, -2, -3	ten eleven translocation enzymes.
TSG	tumour suppressor gene.
TSS	transcription start sites.
TWIST1	twist-related protein 1.
UHRF1	ubiquitin-like PHD and RING finger domain 1.
WGBS	whole-genome bisulphite sequencing.
WoE	weight of evidence.